SCI时时刷

search
Prostate Cancer Survivorship Today: Support that Spans the Journey
American Cancer Society. Key statistics for prostate cancer. Facts and figures 2022. 2022. Atlanta, GA: American Cancer......
Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes
BackgroundUGN-101 can be used for chemoablation of low-grade upper tract urothelial carcinoma (UTUC). The gel can be admin...
The Europa Uomo Patient Reported Outcome Study 2.0—Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making
Available online 31 May 2023Author links open overlay panel, , , , , , AbstractBackgroundTo further strengthen the voice o...
A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non–muscle-invasive Bladder Cancer
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of c...
Immune Checkpoint Inhibitor Toxicity Management in Non–muscle-invasive Bladder Cancer: What Urologists Need To Know
Available online 16 May 2023Author links open overlay panel, , AbstractImmune checkpoint inhibitors (ICIs) have emerged as...
Disparities Associated with Shared Decision-making in Prostate Cancer Screening
Prostate-specific antigen (PSA) is a commonly used tool in screening for prostate cancer. The clinical effectiveness of us...
Current Techniques for En Bloc Transurethral Resection of Bladder Tumor: A Hands-on Guide Through the Energy Landscape
Transurethral resection of bladder tumor (TURBT) is considered the cornerstone of treatment for non–muscle-invasive bladde...
For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy
Available online 6 May 2023Author links open overlay panel, , , , , , , , AbstractGiven the morbidity associated with radi...
Pelvic Organ Preservation in Non–muscle-invasive Bladder Cancer: Less Is More
Bladder cancer is the tenth most common cancer worldwide, and 75% of new diagnoses are non–muscle-invasive bladder cancer ...
Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials
Available online 27 April 2023Author links open overlay panel, , , , , , AbstractBackgroundMany patients discontinue overa...
Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer
BackgroundMolecular signatures in prostate cancer (PCa) tissue can provide useful prognostic information to improve the un...
Physician Perception of Grade Group 1 Prostate Cancer
There are multiple management options for men with grade group 1 (GG 1) prostate cancer (PCa). According to the National C...
Bone Health in Prostate Cancer Survivors: Recent Lessons and Opportunities for Improvement
Prostate cancer survivors have a higher risk of fracture in comparison to the general population. A primary reason is age:...
Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer—An Extensive Multiregional Immunohistochemical Analysis
A broad panel of therapies is available for bladder cancer (BC) patients of all disease stages. However, the challenge for...
When and How To Perform Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer
It has been shown that active surveillance (AS) is an effective approach in managing selected low-risk urological tumors. ...
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume
Two randomized controlled trials recently demonstrated an overall survival benefit with triplet therapy (androgen receptor...
Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer
Available online 7 April 2023Author links open overlay panel, , , , , , , , , , , , AbstractBackgroundNerve-sparing (NS) r...